CBR3 and breast carcinoma: These studies were published between 2018 and 2022 and involved 7 different cancer types, including cervical cancer,[19] colorectal cancer,[11,12] breast cancer,[13,14] glioma,[15] non‐small‐cell lung cancer,[16] lung adenocarcinoma,[17] and osteosarcoma.[18] All of the included studies employed real-time quantitative PCR to measure lncRNA CBR3-AS1 expression, with patients classified into high and low expression groups based on the expression levels of lncRNA CBR3-AS1.